JP2009522239A - トリテルペンキノンおよびトリテルペンフェノール誘導体、ならびに腫瘍および寄生生物性疾患の治療のためのそれらの適用 - Google Patents

トリテルペンキノンおよびトリテルペンフェノール誘導体、ならびに腫瘍および寄生生物性疾患の治療のためのそれらの適用 Download PDF

Info

Publication number
JP2009522239A
JP2009522239A JP2008547980A JP2008547980A JP2009522239A JP 2009522239 A JP2009522239 A JP 2009522239A JP 2008547980 A JP2008547980 A JP 2008547980A JP 2008547980 A JP2008547980 A JP 2008547980A JP 2009522239 A JP2009522239 A JP 2009522239A
Authority
JP
Japan
Prior art keywords
alkyl
group
unsubstituted
substituted
independently hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008547980A
Other languages
English (en)
Japanese (ja)
Inventor
フアン、カルロス、ラカル、サンフアン
アナ、ラミレス、デ、モリナ
モニカ、バニェス、コロネル
アンヘル、グティエレス、ラベロ
アナ、エステベス、ブラウン
ドゥルセ、ヤスミン、メサ、シベリオ
エリサ、ペレス、サカウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Universidad de La Laguna
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Universidad de La Laguna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Universidad de La Laguna filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Publication of JP2009522239A publication Critical patent/JP2009522239A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/723—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic
    • C07C49/727—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/747—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/753—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of polycyclic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
JP2008547980A 2005-12-30 2006-12-29 トリテルペンキノンおよびトリテルペンフェノール誘導体、ならびに腫瘍および寄生生物性疾患の治療のためのそれらの適用 Pending JP2009522239A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200503263A ES2277568B1 (es) 2005-12-30 2005-12-30 Derivados de triterpenoquinona y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.
PCT/EP2006/070276 WO2007077203A2 (en) 2005-12-30 2006-12-29 Triterpenequinone and triterpenephenol derivatives and their application for the treatment of tumors and parasitic diseases

Publications (1)

Publication Number Publication Date
JP2009522239A true JP2009522239A (ja) 2009-06-11

Family

ID=37946257

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008547980A Pending JP2009522239A (ja) 2005-12-30 2006-12-29 トリテルペンキノンおよびトリテルペンフェノール誘導体、ならびに腫瘍および寄生生物性疾患の治療のためのそれらの適用

Country Status (11)

Country Link
EP (1) EP1976533A2 (es)
JP (1) JP2009522239A (es)
KR (1) KR20080083044A (es)
CN (1) CN101351211A (es)
AU (1) AU2006334359A1 (es)
BR (1) BRPI0620845A2 (es)
CA (1) CA2635318A1 (es)
ES (1) ES2277568B1 (es)
MX (1) MX2008008556A (es)
RU (1) RU2008131311A (es)
WO (1) WO2007077203A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007012668A (es) 2005-04-13 2008-03-11 Consejo Superior Investigacion Metodo in vitro para identificar compuestos para terapia del cancer.
WO2009026163A1 (en) * 2007-08-17 2009-02-26 Burnham Institute For Medical Research Compositions and methods for inhibiting growth and metastasis of melanoma
CN101434635B (zh) * 2007-11-16 2012-05-16 上海华拓医药科技发展股份有限公司 一类具抗肿瘤活性的水溶性酚性三萜化合物及其制备方法
US20100068302A1 (en) * 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer
WO2010049173A1 (en) * 2008-10-31 2010-05-06 Cenix Bioscience Gmbh Use of inhibitors of host kinases for the treatment of infectious diseases
JP2013536203A (ja) * 2010-08-23 2013-09-19 スーチョウ・ニューファーマ・カンパニー・リミテッド 特定の化学成分、組成物および方法
EP3364956A4 (en) 2015-10-23 2019-05-01 ERX Pharmaceuticals, Inc. CELASTROL ANALOGUES
US10808005B2 (en) 2016-07-04 2020-10-20 Ixmedicine (Xiamen) Biological Technology Company Limited Ligand for orphan nuclear receptor Nur77 and uses thereof
WO2018019681A1 (en) 2016-07-25 2018-02-01 Nerviano Medical Sciences S.R.L. Purine and 3-deazapurine analogues as choline kinase inhibitors
EP3652177A1 (en) 2017-07-11 2020-05-20 Nerviano Medical Sciences S.r.l. Pyrazolo-quinazoline derivatives as choline kinase inhibitors
WO2020257658A1 (en) 2019-06-20 2020-12-24 University Of Iowa Research Foundation Nanoparticles comprising quinone w methides and compositions for use
CN113827599A (zh) * 2021-09-23 2021-12-24 天津国际生物医药联合研究院 去甲泽拉木醛在抗登革病毒感染中的潜在应用
CN116023426A (zh) * 2022-12-30 2023-04-28 上海海洋大学 去甲泽拉木醛衍生物及其在制备抗癌药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328309A (en) * 1980-07-02 1982-05-04 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Method for producing tripdiolide, triptolide and celastrol
DE4117854A1 (de) * 1991-05-31 1992-12-03 Wiemann Wolfram Verwendung mindestens eines celastroloids als bestandteil fuer ein arzneimittel zur behandlung von erkrankungen des rheumatoiden formenkreises, insbesondere rheumatismus
US5650167A (en) * 1995-11-16 1997-07-22 Dawa Incorporated Method and composition for treating hepatitis B
ES2117950B1 (es) 1996-08-02 1999-09-16 Univ Granada Nuevos compuestos que bloquean la biosintesis de fosforilcolina y su uso como segundo mensajero en proliferacion celular.
CN1155610C (zh) * 2002-11-05 2004-06-30 浙江大学 具有抗氧化和抗肿瘤活性扁蒴藤素系列衍生物及合成方法
US20040220267A1 (en) * 2003-02-07 2004-11-04 Devlin J. P. Derivatives of pentacyclic nortriterpene quinone methides as compounds useful in the treatment of inflammatory, neurodegenerative, and neoplastic diseases

Also Published As

Publication number Publication date
ES2277568A1 (es) 2007-07-01
CA2635318A1 (en) 2007-07-12
ES2277568B1 (es) 2008-04-01
EP1976533A2 (en) 2008-10-08
WO2007077203A2 (en) 2007-07-12
AU2006334359A1 (en) 2007-07-12
KR20080083044A (ko) 2008-09-12
BRPI0620845A2 (pt) 2011-11-22
WO2007077203A3 (en) 2007-08-30
AU2006334359A2 (en) 2008-08-07
CN101351211A (zh) 2009-01-21
MX2008008556A (es) 2008-09-26
RU2008131311A (ru) 2010-02-10

Similar Documents

Publication Publication Date Title
JP2009522239A (ja) トリテルペンキノンおよびトリテルペンフェノール誘導体、ならびに腫瘍および寄生生物性疾患の治療のためのそれらの適用
US20060234956A1 (en) Dicarboxylic acid ester derivatives of ginsenoside, pharmaceutical preparations containing the same, and preparation thereof
JP2009280610A (ja) 腫瘍／癌細胞の増殖の抑制活性を有するガンボージ樹脂から単離した化合物及びその化合物を含む薬学的組成物
Chien et al. Secondary metabolites from the root of Ehretia longiflora and their biological activities
JP2017048195A (ja) ガンおよび他の疾患を治療するための新規化合物
Li et al. Synthesis, antitumor activity evaluation and mechanistic study of novel hederacolchiside A1 derivatives bearing an aryl triazole moiety
JP3285361B2 (ja) コルヒチン骨格化合物、それらの医薬としての用途、及びそれらを含有する組成物
Ulusoy et al. Design, semi-synthesis and examination of new gypsogenin derivatives against leukemia via Abl tyrosine kinase inhibition and apoptosis induction
WO2023125928A1 (zh) Menin抑制剂及其用途
Zhu et al. Design and synthesis of NAD (P) H: Quinone oxidoreductase (NQO1)-activated prodrugs of 23-hydroxybetulinic acid with enhanced antitumor properties
Kang et al. Discovery of a novel water-soluble, rapid-release triptolide prodrug with improved drug-like properties and high efficacy in human acute myeloid leukemia
Munikishore et al. Structurally modified Cyclovirobuxine-D Buxus alkaloids as effective analgesic agents through Cav3. 2 T-Type calcium channel inhibition
Zhang et al. A pair of new tirucallane triterpenoid epimers from the stems of Picrasma quassioides
Liu et al. Dihydromyricetin from Ampelopsis grossedentata and its derivatives: Structural characterization and anti-hepatocellular carcinoma activity
CN110698443A (zh) 一种shp2小分子选择性抑制剂及其在制备抗肺癌药物中的应用
CZ282473B6 (cs) Bis(fenyl)ethanové deriváty, způsob jejich přípravy a farmaceutická kompozice tyto deriváty obsahující
Zhou et al. Structurally diverse terpenoids and their DRAK2 inhibitory activities: A follow-up study on the vulnerable conifer Pseudotsuga forrestii
US9175030B2 (en) Derivatives of avicin D and methods of making and using thereof
Sun et al. Polycyclic polyprenylated acylphloroglucinol derivatives from Hypericum pseudohenryi
TWI227238B (en) Novel pyranocoumarin compounds and their applications
Wang et al. (±)-Yanhusuomide A, a pair of ornithine-fused benzylisoquinoline enantiomers from Corydalis yanhusuo
Zhang et al. Prunolactones AG, proangiogenic isocoumarin derivatives with an unusual 6/6/6/6/6 spiropentacyclic skeleton from the endophytic fungus Phomopsis prunorum
CN115925775A (zh) 三萜类化合物及其制备方法和应用
JP2000229977A (ja) トリデカノリド誘導体及び抗癌剤
EP2951189B1 (fr) Macrolides utiles comme agents anticancereux